Cargando…

Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study

BACKGROUND: Elevated serum phosphorus concentrations are common among maintenance hemodialysis patients. Protein is a major source of dietary phosphate, but restriction of protein intake can result in hypoalbuminemia and protein-energy wasting. We hypothesized that sucroferric oxyhydroxide (SO), a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalantar-Zadeh, Kamyar, Ficociello, Linda H., Parameswaran, Vidhya, Athienites, Nicolaos V., Mullon, Claudy, Kossmann, Robert J., Coyne, Daniel W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820926/
https://www.ncbi.nlm.nih.gov/pubmed/31664928
http://dx.doi.org/10.1186/s12882-019-1582-9
_version_ 1783464045825753088
author Kalantar-Zadeh, Kamyar
Ficociello, Linda H.
Parameswaran, Vidhya
Athienites, Nicolaos V.
Mullon, Claudy
Kossmann, Robert J.
Coyne, Daniel W.
author_facet Kalantar-Zadeh, Kamyar
Ficociello, Linda H.
Parameswaran, Vidhya
Athienites, Nicolaos V.
Mullon, Claudy
Kossmann, Robert J.
Coyne, Daniel W.
author_sort Kalantar-Zadeh, Kamyar
collection PubMed
description BACKGROUND: Elevated serum phosphorus concentrations are common among maintenance hemodialysis patients. Protein is a major source of dietary phosphate, but restriction of protein intake can result in hypoalbuminemia and protein-energy wasting. We hypothesized that sucroferric oxyhydroxide (SO), a potent phosphate binder with a low pill burden, may reduce serum phosphorus levels in hemodialysis patients with hypoalbuminemia without adversely impacting albumin levels or dietary intake of protein. METHODS: We retrospectively examined de-identified data from 79 adult, in-center hemodialysis patients with baseline hypoalbuminemia (≤ 3.5 g/dL) switched to SO as part of routine clinical care for at least 1 year. Temporal changes (3-month intervals from baseline through Q4) in phosphate binder pill burden, serum phosphorous levels, nutritional markers, and equilibrated Kt/V were analyzed. Data from a matched reference group of non-hypoalbuminemic patients (N = 79) switched to SO were also examined. RESULTS: SO therapy was associated with a mean reduction of 45.7 and 45.1% in daily phosphate binder pill burden, and a mean reduction of 0.4 mg/dL and 0.51 mg/dL in serum phosphorus levels for the hypoalbuminemic and non-hypoalbuminemic patients, respectively. Hypoalbuminemic patients demonstrated significant increases in mean serum albumin levels from 3.50 mg/dL at baseline to 3.69, 3.74, 3.70, and 3.69 mg/dL during Q1 through Q4, respectively (P < 0.0001), whereas serum albumin levels remained unchanged in the non-hypoalbuminemic group. CONCLUSIONS: Both hypoalbuminemic and non-hypoalbuminemic patients switching to SO exhibited significant reductions in serum phosphorus concentrations and daily phosphate binder pill burden. Among hypoalbuminemic patients, the initiation of SO therapy was also associated with increases in serum albumin, suggesting therapy may have allowed patients to increase their dietary intake of protein.
format Online
Article
Text
id pubmed-6820926
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68209262019-11-04 Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study Kalantar-Zadeh, Kamyar Ficociello, Linda H. Parameswaran, Vidhya Athienites, Nicolaos V. Mullon, Claudy Kossmann, Robert J. Coyne, Daniel W. BMC Nephrol Research Article BACKGROUND: Elevated serum phosphorus concentrations are common among maintenance hemodialysis patients. Protein is a major source of dietary phosphate, but restriction of protein intake can result in hypoalbuminemia and protein-energy wasting. We hypothesized that sucroferric oxyhydroxide (SO), a potent phosphate binder with a low pill burden, may reduce serum phosphorus levels in hemodialysis patients with hypoalbuminemia without adversely impacting albumin levels or dietary intake of protein. METHODS: We retrospectively examined de-identified data from 79 adult, in-center hemodialysis patients with baseline hypoalbuminemia (≤ 3.5 g/dL) switched to SO as part of routine clinical care for at least 1 year. Temporal changes (3-month intervals from baseline through Q4) in phosphate binder pill burden, serum phosphorous levels, nutritional markers, and equilibrated Kt/V were analyzed. Data from a matched reference group of non-hypoalbuminemic patients (N = 79) switched to SO were also examined. RESULTS: SO therapy was associated with a mean reduction of 45.7 and 45.1% in daily phosphate binder pill burden, and a mean reduction of 0.4 mg/dL and 0.51 mg/dL in serum phosphorus levels for the hypoalbuminemic and non-hypoalbuminemic patients, respectively. Hypoalbuminemic patients demonstrated significant increases in mean serum albumin levels from 3.50 mg/dL at baseline to 3.69, 3.74, 3.70, and 3.69 mg/dL during Q1 through Q4, respectively (P < 0.0001), whereas serum albumin levels remained unchanged in the non-hypoalbuminemic group. CONCLUSIONS: Both hypoalbuminemic and non-hypoalbuminemic patients switching to SO exhibited significant reductions in serum phosphorus concentrations and daily phosphate binder pill burden. Among hypoalbuminemic patients, the initiation of SO therapy was also associated with increases in serum albumin, suggesting therapy may have allowed patients to increase their dietary intake of protein. BioMed Central 2019-10-29 /pmc/articles/PMC6820926/ /pubmed/31664928 http://dx.doi.org/10.1186/s12882-019-1582-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kalantar-Zadeh, Kamyar
Ficociello, Linda H.
Parameswaran, Vidhya
Athienites, Nicolaos V.
Mullon, Claudy
Kossmann, Robert J.
Coyne, Daniel W.
Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study
title Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study
title_full Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study
title_fullStr Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study
title_full_unstemmed Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study
title_short Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study
title_sort changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820926/
https://www.ncbi.nlm.nih.gov/pubmed/31664928
http://dx.doi.org/10.1186/s12882-019-1582-9
work_keys_str_mv AT kalantarzadehkamyar changesinserumalbuminandothernutritionalmarkerswhenusingsucroferricoxyhydroxideasphosphatebinderamonghemodialysispatientsahistoricalcohortstudy
AT ficociellolindah changesinserumalbuminandothernutritionalmarkerswhenusingsucroferricoxyhydroxideasphosphatebinderamonghemodialysispatientsahistoricalcohortstudy
AT parameswaranvidhya changesinserumalbuminandothernutritionalmarkerswhenusingsucroferricoxyhydroxideasphosphatebinderamonghemodialysispatientsahistoricalcohortstudy
AT athienitesnicolaosv changesinserumalbuminandothernutritionalmarkerswhenusingsucroferricoxyhydroxideasphosphatebinderamonghemodialysispatientsahistoricalcohortstudy
AT mullonclaudy changesinserumalbuminandothernutritionalmarkerswhenusingsucroferricoxyhydroxideasphosphatebinderamonghemodialysispatientsahistoricalcohortstudy
AT kossmannrobertj changesinserumalbuminandothernutritionalmarkerswhenusingsucroferricoxyhydroxideasphosphatebinderamonghemodialysispatientsahistoricalcohortstudy
AT coynedanielw changesinserumalbuminandothernutritionalmarkerswhenusingsucroferricoxyhydroxideasphosphatebinderamonghemodialysispatientsahistoricalcohortstudy